

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Examiner Signature	/Meera Natarajan/	Date Considered	07/16/2008
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation, designation, and classification (optional). See Kinds Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual inventor. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/568,544</td> </tr> <tr> <td>Filing Date</td> <td>September 22, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Kannagi</td> </tr> <tr> <td>Art Unit</td> <td>1643</td> </tr> <tr> <td>Examiner Name</td> <td>Meera Natarajan</td> </tr> <tr> <td>Attorney Docket Number</td> <td>1680/12</td> </tr> </table>		Application Number	10/568,544	Filing Date	September 22, 2006	First Named Inventor	Kannagi	Art Unit	1643	Examiner Name	Meera Natarajan	Attorney Docket Number	1680/12
Application Number	10/568,544														
Filing Date	September 22, 2006														
First Named Inventor	Kannagi														
Art Unit	1643														
Examiner Name	Meera Natarajan														
Attorney Docket Number	1680/12														
Sheet	2	of	2												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.N./	2	Bruhli et al., "Minimal sulfated carbohydrates for recognition by L-selectin and the MECA-79 antibody," The Journal of Biological Chemistry, Vol. 275, No. 42, pgs. 32642-32648 (October 20, 2000).	
/M.N./	3	Izawa et al., "Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer," Cancer Research, Vol. 60, No. 5, pgs. 1410-1416 (March 1, 2000).	
/M.N./	4	Jin Kyu Lee et al., "Cloning and characterization of a mammalian N-acetylglucosamine-6-sulfotransferase that is highly restricted to intestinal tissue," Biochemical and Biophysical Research Communications, Vol. 2, No. 263, pgs. 543-549 (September 1999).	
/M.N./	5	Kimura et al., "Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by cotransfection of α -1 \rightarrow 3 fucosyltransferase VII and newly cloned G1cNAc6-S-sulfotransferase cDNA," Proceedings of the National Academy of Sciences of USA, Vol. 96, pgs. 4530-4535 (April 1999).	
/M.N./	6	Seko et al., "Biochemical differences between two types of N-acetylglucosamine-6-sulfotransferases in human colonic adenocarcinomas and the adjacent normal mucosa: specific expression of a G1cNAc \rightarrow 6S-sulfotransferase in mucinous adenocarcinoma," Glycobiology, Vol. 10, No. 9, pgs. 919-929 (September 2000).	
/M.N./	7	Seko et al., "Ectopic expression of a G1cNAc 6-O-sulfotransferase, G1cNAc6ST-2, in colonic mucinous adenocarcinoma," Glycobiology, IRL Press, GB, Vol. 12, No. 6, pgs. 379-388 (2002).	
/M.N./	8	Streeter et al., "Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes," The Journal of Cell Biology, Vol. 107, No. 5, pgs. 1853-1862 (November 1990) 1988	
/M.N./	9	Supplementary European Search Report for European Patent Application No. 04747273.3 - 1223 PCT/JP2004009805 dated April 18, 2008.	
/M.N./	10	Uchimura et al., "Specificities of N-acetylglucosamine-6-O-sulfotransferases in relation to L-selectin ligand synthesis and tumor-associated enzyme expression," Journal of Biological Chemistry, Vol. 277, No. 6, pgs. 3979-3984 (February 8, 2002).	

Examiner Signature	/Meera Natarajan/	Date Considered	07/16/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.